Patricia M. Danzon – författare
Visar alla böcker från författaren Patricia M. Danzon. Handla med fri frakt och snabb leverans.
6 produkter
The Oxford Handbook of the Economics of the Biopharmaceutical Industry
Inbunden, 2012
3177 kr
Lägg i varukorg
The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek …
Oxford Handbook of the Economics of the Biopharmaceutical Industry
Av Sean Nicholson, Patricia M. Danzon
E-bok, 2012
2039 kr
Lägg i varukorg
The biopharmaceutical industry has been a major driver of technological change in health care, producing unprecedented benefits for patients, cost challenges for payers, and profits for shareholders. As consumers and companies benefit from access to new drugs, policymakers around the globe seek …
Rate Regulation of Workers' Compensation Insurance
Av Patricia M. Danzon, Scott E. Harrington
Häftad, 1998
210 kr
Lägg i varukorg
The authors demonstrate how regulation intended to control costs can exacerbate cost growth by subsidizing high-risk activities and firms at the expense of low-risk activities and firms.
Pharmaceutical Price Regulation
National Policies Versus Global Interests
Häftad, 1998
216 kr
Lägg i varukorg
This study examines the effect of existing regulations on US pharmaceutical firms. The author explores the indirect spillovers from the regulatory use of international price comparisons and the threat from parallel trade, concluding that competition promises more efficiency and incentives.
Global Budgets Versus Competitive Cost-control Strategies
Häftad, 1994
149 kr
Lägg i varukorg
This book discusses how global budgets relate to competitive cost-control strategies.
Price Comparisons for Pharmaceuticals
A Review of U.S. and Cross-national Studies
Häftad, 1999
149 kr
Lägg i varukorg
Drug coverage for seniors is better addressed by private-sector plans than by forcing manufacturers to offer Federal Supply Schedule discounts to the retail sector.
